Implications of Delayed Testosterone Recovery in Patients with Prostate Cancer

Mark A Preston; Agnes Hong; Robert Dufour; Jessica R Marden; Noam Y Kirson; Sergio C Gatoulis; Serena Kongara; Raj Gandhi; Alicia K Morgans

doi:10.1016/j.euros.2023.12.003

Implications of Delayed Testosterone Recovery in Patients with Prostate Cancer

Eur Urol Open Sci. 2024 Jan 11:60:32-35. doi: 10.1016/j.euros.2023.12.003. eCollection 2024 Feb.

Authors

Mark A Preston¹, Agnes Hong², Robert Dufour³, Jessica R Marden⁴, Noam Y Kirson⁴, Sergio C Gatoulis², Serena Kongara⁴, Raj Gandhi³, Alicia K Morgans⁵

Affiliations

¹ Brigham and Women's Hospital, Boston, MA, USA.
² Pfizer Inc., New York, NY, USA.
³ Myovant Sciences, Inc., Brisbane, CA, USA.
⁴ Analysis Group, Inc., Boston, MA, USA.
⁵ Dana-Farber Cancer Institute, Boston, MA, USA.

Abstract

To assess the clinical impact of delayed testosterone recovery (TR) following the discontinuation of medical androgen deprivation therapy (ADT), a retrospective, longitudinal analysis was conducted in adult males with prostate cancer using the Optum® de-identified Electronic Health Record data set and Optum® Enriched Oncology Data (2010-2021). Of 3875 patients who initiated and discontinued ADT, 1553 received one or more testosterone-level tests within the 12 mo following discontinuation and were included in this study. These 1553 patients were categorized into two cohorts: 25% as TR (testosterone levels >280 ng/dl at any test within 12 mo following ADT discontinuation) and 75% as non-TR. At baseline, non-TR patients were older, had lower testosterone levels, and were more likely to have diabetes, hyperlipidemia, and hypertension, but less likely to have sexual dysfunction. After adjustment for baseline characteristics, the TR cohort had a lower risk of new-onset diabetes (hazard ratio [HR] 0.47; 95% confidence interval [CI] 0.27-0.79), trended toward a lower risk of new-onset depression (HR 0.58; 95% CI 0.33-1.02), and had a higher likelihood of seeking treatment for sexual dysfunction (HR 1.33; 95% CI 0.99-1.78) versus the non-TR cohort. These findings support monitoring testosterone levels after ADT discontinuation to manage potential long-term comorbidities in patients with prostate cancer.

Patient summary: This real-world analysis of males with prostate cancer who were treated with medical androgen deprivation therapy (ADT) found that most patients did not have their testosterone level checked in the 12 mo after stopping ADT. Of those who did, 75% did not achieve normal testosterone levels (>280 ng/dl), and these patients were more likely to experience new-onset diabetes than those who achieved normal testosterone levels. These results suggest that to ensure effective clinical decision-making, physicians should check patients' testosterone levels after stopping ADT.

Keywords: Androgen deprivation therapy; Prostate cancer; Real-world study; Testosterone recovery.